Radius Health shares are trading lower after the company announced its wearABLe trial evaluating Abaloparatide Transdermal System did not meet its primary endpoint.

by | Dec 8, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.